Please login to the form below

Not currently logged in
Email:
Password:

GSK's H1N1 vaccine gains EU approval

GlaxoSmithKline has confirmed that it has been granted a marketing authorisation by the European Commission for its H1N1 vaccine

GlaxoSmithKline (GSK) has confirmed that it has been granted a marketing authorisation for Pandemrix, its H1N1 vaccine, from the European Commission.

Jean Stéphenne, president of GlaxoSmithKline Biologicals, said: "Following the Commission's approval we expect to commence shipments of Pandemrix to European governments from next week [w/c October 5]."

The European Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion and recommended approval of Pandemrix on September 25. Trials of the vaccine began in August and demonstrated that after one dose the vaccine can provide a strong immune response that exceeds the immunogenic criteria defined by international licensing authorities for a pandemic influenza vaccine.

1st October 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics